Table 2. Unadjusted and adjusted Cox proportional hazards analysis of the impact of RBM3 median protein expression on overall and recurrence free survival according to adjuvant treatment.
| Death within 5 years | Recurrence | |||||
|---|---|---|---|---|---|---|
| HR (95% CI) | n (events, %) | p† | HR (95% CI) | n (events, %) | p† | |
| All | ||||||
| No adjuvant treatment | ||||||
| RBM3 low | 1.00 | 48 (29, 60.4%) | 1 | 48 (26, 54.2%) | ||
| RBM3 high | 1.85 (1.12–3.06) | 43 (33, 76.7%) | 2.00 (1.20–3.33) | 43 (34, 79.1%) | ||
| 2.04 (1.14–3.67) | 2.12 (1.13–3.96) | |||||
| Any adjuvant treatment* | 0.003 | 0.009 | ||||
| RBM3 low | 1 | 35 (27, 77.1%) | 1 | 35 (28, 80.0%) | ||
| RBM3 high | 0.60 (0.34–1.05) | 40 (22, 55.0%) | 0.76 (0.45–1.29) | 40 (28, 70.0%) | ||
| 0.24 (0.12–0.49) | 0.31 (0.16–0.59) | |||||
| Pancreatobiliary type | ||||||
| No adjuvant treatment | ||||||
| RBM3 low | 1 | 22 (14, 63.6%) | 1 | 22 (13, 59.1%) | ||
| RBM3 high | 2.49 (1.27–4.86) | 26 (24, 92.3%) | 2.86 (1.45–5.65) | 26 (26, 100%) | ||
| 4.25 (1.52–11.87) | 2.13 (0.81–5.64) | |||||
| Any adjuvant treatment* | < 0.001 | < 0.001 | ||||
| RBM3 low | 1 | 24 (22, 91.7%) | 1 | 24 (22, 91.7%) | ||
| RBM3 high | 0.45 (0.24–0.85) | 33 (21, 63.6%) | 0.60 (0.33–1.06) | 33 (26, 78.8%) | ||
| 0.41 (0.21–0.80) | 0.36 (0.19–0.69) | |||||
Multivariable analysis adjusted for age, gender, tumor origin, tumor size, T-stage, N-stage, differentiation grade, involved margins, lymphatic growth, vascular growth, perineural growth and growth in peripancreatic fat.
†p value for term of interaction by Cox multivariable analysis including treatment, the binary covariate RBM3 expression, any vs no treatment and a term of interaction.
*The majority of patients received gemcitabine alone (n = 51 and n = 44, respectively) or in combination (n = 6 and n = 4, respectively).